X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (47529) 47529
Book Review (12709) 12709
Publication (2944) 2944
Newsletter (683) 683
Book Chapter (486) 486
Book / eBook (252) 252
Newspaper Article (246) 246
Conference Proceeding (175) 175
Magazine Article (51) 51
Trade Publication Article (49) 49
Government Document (42) 42
Dissertation (31) 31
Data Set (10) 10
Web Resource (6) 6
Presentation (3) 3
Paper (2) 2
Journal / eJournal (1) 1
Reference (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (37919) 37919
humans (35054) 35054
male (19806) 19806
female (18730) 18730
middle aged (14678) 14678
aged (11618) 11618
adult (10949) 10949
urology & nephrology (10395) 10395
treatment outcome (7606) 7606
risk factors (6422) 6422
care and treatment (5862) 5862
animals (5547) 5547
transplantation (5243) 5243
surgery (5116) 5116
medicine & public health (5114) 5114
pharmacology & pharmacy (4735) 4735
oncology (4652) 4652
retrospective studies (4552) 4552
kidneys (4420) 4420
mortality (4358) 4358
analysis (4355) 4355
research (4267) 4267
cancer (4179) 4179
kidney diseases (4147) 4147
hemodialysis (4106) 4106
health aspects (4105) 4105
aged, 80 and over (4010) 4010
nephrology (3895) 3895
renal dialysis (3788) 3788
kidney transplantation (3778) 3778
safety (3750) 3750
patients (3474) 3474
therapy (3356) 3356
hypertension (3260) 3260
abridged index medicus (3163) 3163
prospective studies (3013) 3013
adolescent (2965) 2965
time factors (2955) 2955
chronic kidney failure (2791) 2791
drug therapy (2771) 2771
kidney failure, chronic - therapy (2709) 2709
renal function (2688) 2688
chronic kidney-disease (2679) 2679
carcinoma, renal cell (2649) 2649
chronic kidney disease (2534) 2534
dialysis (2531) 2531
cardiac & cardiovascular systems (2480) 2480
disease (2452) 2452
follow-up studies (2447) 2447
risk (2398) 2398
immunology (2382) 2382
management (2371) 2371
medical research (2356) 2356
renal-cell carcinoma (2349) 2349
efficacy (2347) 2347
clinical trials (2313) 2313
medicine, general & internal (2309) 2309
pharmacokinetics (2297) 2297
glomerular filtration rate (2278) 2278
young adult (2275) 2275
survival (2266) 2266
renal cell carcinoma (2213) 2213
medicine (2202) 2202
child (2194) 2194
kidney (2160) 2160
prognosis (2138) 2138
internal medicine (2096) 2096
diagnosis (2076) 2076
outcomes (2043) 2043
kidney neoplasms - pathology (1984) 1984
renal-function (1917) 1917
complications and side effects (1873) 1873
renal-transplantation (1857) 1857
studies (1850) 1850
pediatrics (1841) 1841
stage renal-disease (1841) 1841
urology (1839) 1839
peripheral vascular disease (1830) 1830
diabetes (1819) 1819
usage (1806) 1806
double-blind (1774) 1774
immunosuppressive agents - therapeutic use (1762) 1762
medicine, experimental (1743) 1743
metastasis (1730) 1730
rats (1723) 1723
dose-response relationship, drug (1722) 1722
tumors (1706) 1706
carcinoma, renal cell - drug therapy (1699) 1699
risk assessment (1695) 1695
trial (1682) 1682
complications (1669) 1669
hemodialysis-patients (1652) 1652
acute-renal-failure (1639) 1639
kidney neoplasms - drug therapy (1633) 1633
prevention (1630) 1630
research article (1617) 1617
renal failure (1614) 1614
article (1613) 1613
children (1601) 1601
patient outcomes (1571) 1571
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (169) 169
Collection Dvlpm't (Acquisitions) - Closed Orders (9) 9
Humber River Regional Hospital - Church Stacks (6) 6
UofT at Mississauga - Stacks (6) 6
Online Resources - Online (5) 5
Scarborough Hospital - General (5) 5
St. Augustine's Seminary - Stacks (4) 4
St. Michael's College (John M. Kelly) - 2nd Floor (4) 4
St. Michael's Hospital - Stacks (4) 4
UofT at Scarborough - Stacks (4) 4
Humber River Regional Hospital - Finch Stacks (3) 3
Scarborough Hospital - Birchmount (3) 3
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (3) 3
Toronto East General Hospital - Stacks (3) 3
UTL at Downsview - May be requested (3) 3
Victoria University E.J. Pratt - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Holland Bloorview Kids Rehabilitation - Stacks (2) 2
Stacks (2) 2
Trinity College (John W Graham) - Stacks (2) 2
Trinity College (John W Graham) - Wycliffe Storage (2) 2
Credit Valley Hospital - Reference (1) 1
Credit Valley Hospital - Stacks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Gerstein Science - May be requested in 6-10 wks (1) 1
Humber River Regional Hospital - Church Reference (1) 1
Knox College (Caven) - Stacks (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Law (Bora Laskin) - Stacks (1) 1
Markham Stouffville Hospital - Stacks (1) 1
New College (Ivey) - Stacks (1) 1
Providence Healthcare - Stacks (1) 1
Providence Healthcare - Withdrawn (1) 1
Robarts - Stacks (1) 1
Scarborough Hospital - Grace (1) 1
St Josephs Health Centre - Stacks (1) 1
St. Michael's Hospital - Online (1) 1
Toronto East General Hospital - Online (1) 1
Trillium Health Centre - Missing (1) 1
Trillium Health Centre - Online (1) 1
West Park Healthcare Centre - Online (1) 1
West Park Healthcare Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (47966) 47966
German (291) 291
French (251) 251
Spanish (226) 226
Japanese (106) 106
Chinese (86) 86
Russian (83) 83
Korean (61) 61
Italian (40) 40
Portuguese (35) 35
Polish (34) 34
Turkish (22) 22
Swedish (6) 6
Czech (5) 5
Dutch (4) 4
Slovenian (3) 3
Croatian (2) 2
Hebrew (2) 2
Hungarian (2) 2
Serbian (2) 2
Arabic (1) 1
Danish (1) 1
Finnish (1) 1
Indonesian (1) 1
Lithuanian (1) 1
Persian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2012, Volume 366, Issue 26, pp. 2443 - 2454
Releasing T cells from inhibitory control has been a strategy exploited by the anti–CTLA-4 antibody ipilimumab. Now an antibody against a second checkpoint... 
CELL LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | THERAPY | SOLID TUMORS | RESPONSE CRITERIA | IMMUNOTHERAPY | GUIDELINES | B7 FAMILY | B7-H1 | ANTITUMOR IMMUNITY | BLOCKADE | Neoplasms - metabolism | Antibodies, Monoclonal - pharmacology | Humans | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - metabolism | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Melanoma - drug therapy | Adult | Female | Ligands | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Carcinoma, Renal Cell - drug therapy | Prostatic Neoplasms - drug therapy | Drugs | Dose-response relationship (Biochemistry) | Immune response | Anti-antibodies | Dosage and administration | Product/Service Evaluations | Regulation | Research | Drug therapy | Cancer | Fees & charges | Kidneys | Stock options | PD-1 protein | Laboratories | Toxicity | Tumor cells | Body weight | Lung cancer | Colorectal carcinoma | Colorectal cancer | Melanoma | Licenses | Lymphocytes T | Patients | Castration | PD-L1 protein | Antitumor activity | Prostate cancer | Drug dosages | Prostate | Clear cell-type renal cell carcinoma | Tumors | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2012, Volume 366, Issue 26, pp. 2455 - 2465
Antibodies to PD-1 protein and to one of its ligands, PD-L1, have shown antitumor activity. Unleashing T cells from inhibitory signals may be a strategy to... 
MEDICINE, GENERAL & INTERNAL | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | SOLID TUMORS | RESPONSE CRITERIA | CELL ACTIVATION | IMMUNOTHERAPY | B7 FAMILY | ANTITUMOR IMMUNITY | CLINICAL ACTIVITY | PHASE-I | T-CELLS | Neoplasms - metabolism | Humans | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - metabolism | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Stomach Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Melanoma - drug therapy | Adult | Female | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Carcinoma, Renal Cell - drug therapy | Ovarian Neoplasms - drug therapy | Intravenous administration | Kidneys | Immune response | Disease | PD-1 protein | Tumor cells | Lung | Colorectal carcinoma | Body weight | Melanoma | Lymphocytes T | Breast cancer | Stomach cancer | Patients | Ovarian cancer | Pancreatic cancer | PD-L1 protein | Antitumor activity | Ligands | Autoimmune diseases | Gastric cancer | Clear cell-type renal cell carcinoma | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Circulation, ISSN 0009-7322, 03/2014, Volume 129, Issue 9, pp. 961 - 970
BACKGROUND—Renal impairment increases the risk of stroke and bleeding in patients with atrial fibrillation. In the Randomized Evaluation of Long-Term... 
atrial fibrillation | renal insufficiency | anticoagulants | dabigatran | stroke | hemorrhage | warfarin | CARDIAC & CARDIOVASCULAR SYSTEMS | RISK-FACTORS | MANAGEMENT | PREVENTION | APIXABAN | IMPAIRMENT | GLOMERULAR-FILTRATION-RATE | PERIPHERAL VASCULAR DISEASE | EQUATION | SYSTEMIC EMBOLISM | Kidney - physiology | Humans | Middle Aged | Warfarin - adverse effects | Male | Dabigatran | Atrial Fibrillation - physiopathology | Glomerular Filtration Rate - physiology | Warfarin - pharmacology | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Glomerular Filtration Rate - drug effects | beta-Alanine - pharmacology | Aged, 80 and over | Female | Stroke - epidemiology | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Embolism - epidemiology | Benzimidazoles - therapeutic use | beta-Alanine - adverse effects | Kidney - drug effects | Atrial Fibrillation - drug therapy | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Internationality | Models, Biological | Anticoagulants - pharmacology | Benzimidazoles - pharmacology | Aged | Complications and side effects | Usage | Care and treatment | Warfarin | Atrial fibrillation | Dabigatran etexilate | Kidney diseases | Comparative analysis | Risk factors | Index Medicus | Abridged Index Medicus | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 16, pp. 4617 - 4624
Purpose: Bronchial and gastroenteropancreatic neuroendocrine tumors (NET) are slow-growing tumors, which frequently express somatostatin receptors on their... 
RADIOLABELED SOMATOSTATIN ANALOG | Y-90-DOTATOC | GRADING SYSTEM | PRRT | LU-177-OCTREOTATE | PROGNOSTIC-FACTORS | ONCOLOGY | GUIDELINES | RECEPTOR RADIONUCLIDE THERAPY | CHEMOTHERAPY | LANREOTIDE | Outcome Assessment (Health Care) - methods | Humans | Middle Aged | Male | Intestinal Neoplasms - radiotherapy | Leukemia - etiology | Time Factors | Aged, 80 and over | Organometallic Compounds - therapeutic use | Adult | Female | Stomach Neoplasms - radiotherapy | Acute Disease | Octreotide - analogs & derivatives | Organometallic Compounds - adverse effects | Kaplan-Meier Estimate | Octreotide - adverse effects | Pancreatic Neoplasms - radiotherapy | Treatment Outcome | Octreotide - therapeutic use | Myelodysplastic Syndromes - etiology | Neuroendocrine Tumors - radiotherapy | Bronchial Neoplasms - radiotherapy | Outcome Assessment (Health Care) - statistics & numerical data | Aged | Radiopharmaceuticals - adverse effects | Radiopharmaceuticals - therapeutic use | Therapy | Membranes | Toxicity | Leukemia | Liver | Radioisotopes | Myelodysplastic syndrome | Metastases | Confidence intervals | Receptors | Safety engineering | Somatostatin | Safety | Effectiveness | Kidneys | Cell membranes | Cell membranes (biology) | Survival | Patients | Lutetium | Experimental design | Renal failure | Somatostatin receptors | Tumors | Cancer | Neuroendocrine tumors | Index Medicus
Journal Article